Voyager Acquisition Corp.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Adeel Rouf
- Full Time Employees
- 3
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 131 Concord Street Brooklyn NY Cayman Islands 11201
- IPO Date
- Sep 30, 2024
- Website
- voyageracq.com
- Similar Companies
- Business
- Voyager Acquisition Corp. operates as a special purpose acquisition company, structured to facilitate a business combination such as a merger, share exchange, or asset acquisition. The company initially concentrated its search on opportunities within the healthcare or healthcare-related sectors, as well as technology and technology-enabled services. Having completed its initial public offering in August 2024, raising $253 million, the entity has since progressed beyond its exploratory phase. Voyager Acquisition Corp. has now entered into a definitive agreement for a business combination with VERAXA Biotech AG, a biopharmaceutical firm, aiming to establish a publicly traded biopharmaceutical company. A Form F-4 Registration Statement has been filed with the SEC, with VERAXA Biotech anticipating a NASDAQ listing later in 2025 through this de-SPAC transaction.
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG
Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG
Crossingbridge Advisors LLC Acquires Shares of 46,779 Voyager Acquisition Corp. $VACH
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.
Contrasting Blaize (NASDAQ:BZAI) & Voyager Acquisition (NASDAQ:VACH)
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger - CRTAF, LCTC, VACH, and EFIN
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer